|Mr. Lonnel Coats||Chief Exec. Officer, Pres and Director||1.05M||N/A||52|
|Mr. Jeffrey L. Wade J.D.||Chief Financial Officer and Exec. VP of Corp. & Admin. Affairs||610.38k||N/A||52|
|Dr. Alan J. Main Ph.D.||Exec. VP of Commercial Supply Operations||518.41k||N/A||63|
|Dr. Pablo Lapuerta M.D.||Chief Medical Officer and Exec. VP||541.51k||N/A||54|
|Dr. Praveen Tyle Ph.D.||Exec. VP of R&D||487.38k||N/A||57|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 7.